<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title>PLoS ONE</journal-title><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">07-PONE-RA-01234R1</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0002546</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Cardiovascular Disorders</subject><subject>Genetics and Genomics/Genetics of Disease</subject><subject>Diabetes and Endocrinology/Type 1 Diabetes</subject><subject>Diabetes and Endocrinology/Type 2 Diabetes</subject><subject>Nephrology/Chronic Kidney Disease</subject><subject>Ophthalmology/Diabetic Retinopathy</subject></subj-group></article-categories><title-group><article-title>Association between <italic>LTA</italic>, <italic>TNF</italic> and <italic>AGER</italic> Polymorphisms and Late Diabetic Complications</article-title><alt-title alt-title-type="running-head"><italic>LTA</italic>, <italic>TNF</italic> and <italic>AGER</italic> in Diabetes</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lindholm</surname><given-names>Eero</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bakhtadze</surname><given-names>Ekaterina</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Cilio</surname><given-names>Corrado</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Agardh</surname><given-names>Elisabet</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Groop</surname><given-names>Leif</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Agardh</surname><given-names>Carl-David</given-names></name><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff id="aff1"><addr-line>Department of Clinical Sciences, University Hospital MAS, Lund University, Lund, Sweden</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Zhang</surname><given-names>Cuilin</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">NICHD/National Institutes of Health, United States of America</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>Eero.Lindholm@med.lu.se</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: EL CA. Performed the experiments: EL EB. Analyzed the data: EL. Contributed reagents/materials/analysis tools: LG CC CA EA. Wrote the paper: LG EL CA EB EA.</p></fn></author-notes><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>25</day><month>6</month><year>2008</year></pub-date><volume>3</volume><issue>6</issue><elocation-id>e2546</elocation-id><history><date date-type="received"><day>7</day><month>5</month><year>2007</year></date><date date-type="accepted"><day>15</day><month>5</month><year>2008</year></date></history><copyright-statement>Lindholm et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement><copyright-year>2008</copyright-year><abstract><sec><title>Background</title><p>Several candidate genes on the short arm of chromosome 6 including the <italic>HLA</italic> locus, <italic>TNF</italic>, <italic>LTA</italic> and <italic>AGER</italic> could be associated with late diabetic complications. The aim of our study was therefore to explore whether polymorphisms (<italic>TNF</italic> -308 G&#x02192;A, <italic>LTA</italic> T60N C&#x02192;A and <italic>AGER</italic> -374 T&#x02192;A) in these genes alone or together (as haplotypes) increased the risk for diabetic complications.</p></sec><sec><title>Methodology/Principal Findings</title><p>The studied polymorphisms were genotyped in 742 type 1 and 2957 type 2 diabetic patients as well as in 206 non-diabetic control subjects. The Haploview program was used to analyze putative linkage disequilibrium between studied polymorphisms. The <italic>TNF</italic>, <italic>LTA</italic> and <italic>AGER</italic> polymorphisms were associated with the <italic>HLA-DQB1</italic> risk genotypes. The <italic>AGER</italic> -374 A allele was more common in type 1 diabetic patients with than without diabetic nephropathy (31.2 vs. 28.4&#x00025;, p&#x0200a;&#x0003d;&#x0200a;0.007). In a logistic regression analysis, the <italic>LTA</italic> but not the <italic>AGER</italic> polymorphism was associated with diabetic nephropathy (OR 2.55&#x0005b;1.11&#x02013;5.86&#x0005d;, p&#x0200a;&#x0003d;&#x0200a;0.03). The <italic>AGER</italic> -374 A allele was associated with increased risk of sight threatening retinopathy in type 2 diabetic patients (1.65&#x0005b;1.11&#x02013;2.45&#x0005d;, p&#x0200a;&#x0003d;&#x0200a;0.01) and also with increased risk for macrovascular disease in type 1 diabetic patients (OR 2.05&#x0005b;1.19&#x02013;3.54&#x0005d;, p&#x0200a;&#x0003d;&#x0200a;0.01), but with decreased risk for macrovascular disease in type 2 diabetic patients (OR 0.66&#x0005b;0.49&#x02013;0.90&#x0005d;, p&#x0200a;&#x0003d;&#x0200a;0.009). The <italic>TNF</italic> A allele was associated with increased risk for macrovascular complications in type 2 (OR 1.53 &#x0005b;1.04&#x02013;2.25&#x0005d;, p&#x0200a;&#x0003d;&#x0200a;0.03, but not in type 1 diabetic patients.</p></sec><sec><title>Conclusions/Significance</title><p>The association between diabetic complications and <italic>LTA</italic>, <italic>TNF</italic> and <italic>AGER</italic> polymorphisms is complex, with partly different alleles conferring susceptibility in type 1 and type 2 diabetic patients. We can not exclude the possibility that the genes are part of a large haplotype block that also includes <italic>HLA-DQB1</italic> risk genotypes.</p></sec></abstract><counts><page-count count="6"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>The etiology of diabetic complications is complex, and inflammation may play a role <xref ref-type="bibr" rid="pone.0002546-Navarro1">&#x0005b;1&#x0005d;</xref>. The mRNA expression for pro-inflammatory cytokines such as IL-1 and Tumor Necrosis Factor Alpha (TNF-&#x003b1;) is increased in the retina and animal studies suggest that inhibition of TNF-&#x003b1; has beneficial effects in prevention of diabetic retinopathy <xref ref-type="bibr" rid="pone.0002546-Joussen1">&#x0005b;2&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002546-Joussen2">&#x0005b;3&#x0005d;</xref>. Recently, we have shown that type 1 diabetic patients with proliferative retinopathy have increased levels of TNF- &#x003b1; <xref ref-type="bibr" rid="pone.0002546-Gustavsson1">&#x0005b;4&#x0005d;</xref>. Similarly, inflammatory markers are elevated in diabetic nephropathy <xref ref-type="bibr" rid="pone.0002546-DallaVestra1">&#x0005b;5&#x0005d;</xref> and inflammation is associated with development of macrovascular complications such as myocardial infarction <xref ref-type="bibr" rid="pone.0002546-Libby1">&#x0005b;6&#x0005d;</xref>. TNF-&#x003b1; and lymphotoxin-&#x003b1; (LT-&#x003b1;, also known as TNF-&#x003b2;) belong to the same TNF family and are encoded by the same gene cluster. TNF-&#x003b1; is mainly produced by activated macrophages and LT-&#x003b1; by T, B and natural killer cell lymphocytes <xref ref-type="bibr" rid="pone.0002546-Makhatadze1">&#x0005b;7&#x0005d;</xref>. Promoter variants -308A&#x02192;G and -238G&#x02192;A in the gene coding for TNF-&#x003b1; (<italic>TNF</italic>) affect transcriptional regulation of the gene coding for LT-&#x003b1; (<italic>LTA</italic>) <xref ref-type="bibr" rid="pone.0002546-Knight1">&#x0005b;8&#x0005d;</xref>. The receptor for advanced glycation end products (RAGE) is also mainly considered as an intracellular signal and transducer or proinflammatory peptide <xref ref-type="bibr" rid="pone.0002546-Vlassara1">&#x0005b;9&#x0005d;</xref>.</p><p><italic>LTA</italic>, <italic>TNF</italic> and the gene encoding for RAGE (<italic>AGER</italic>) are all located within the MHC complex on the short arm of chromosome 6. The HLA locus is among the most polymorphic in the human genome. Some studies have suggested a direct role of HLA in development of diabetic nephropathy <xref ref-type="bibr" rid="pone.0002546-Dyck1">&#x0005b;10&#x0005d;</xref>, retinopathy <xref ref-type="bibr" rid="pone.0002546-Agardh1">&#x0005b;11&#x0005d;</xref> and macrovascular disease <xref ref-type="bibr" rid="pone.0002546-Dahlen1">&#x0005b;12&#x0005d;</xref>. Since this region also harbours a variety of other genes involved in inflammation, the results could also reflect variation in other genes than HLA. We have recently shown <italic>AGER</italic> -374T&#x02192;A polymorphism to be associated with diabetic nephropathy and possibly with retinopathy in type 1, but not in type 2 diabetic patients <xref ref-type="bibr" rid="pone.0002546-Lindholm1">&#x0005b;13&#x0005d;</xref>. The results concerning the risk allele (A) in the <italic>AGER</italic> gene were in conflict with a previous study <xref ref-type="bibr" rid="pone.0002546-PetterssonFernholm1">&#x0005b;14&#x0005d;</xref>, and a possible explanation could be that the <italic>AGER</italic> gene is in linkage disequilibrium with other genes, such as <italic>TNF</italic> and <italic>LTA</italic>.</p><p>Variation in <italic>TNF</italic> and <italic>LTA</italic> genes has been associated with diabetic nephropathy <xref ref-type="bibr" rid="pone.0002546-Manchanda1">&#x0005b;15&#x0005d;</xref>, retinopathy <xref ref-type="bibr" rid="pone.0002546-Kumaramanickavel1">&#x0005b;16&#x0005d;</xref> as well as with cardiovascular and cerebrovascular disease <xref ref-type="bibr" rid="pone.0002546-Um1">&#x0005b;17&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002546-Bernard1">&#x0005b;18&#x0005d;</xref>. A large genome-scan in Japanese patients identified a susceptibility locus for myocardial infarction on chromosome 6p21 <xref ref-type="bibr" rid="pone.0002546-Ozaki1">&#x0005b;19&#x0005d;</xref>, especially the 256A&#x02192;G and T60N (also referred to as T26N in some studies) variants in the <italic>LTA</italic> gene, were associated with myocardial infarction. However, a recent, rather large study from USA could neither confirm the association with myocardial infarction, nor the association with inflammatory biomarkers <xref ref-type="bibr" rid="pone.0002546-Asselbergs1">&#x0005b;20&#x0005d;</xref>.</p><p>The <italic>TNF</italic>/<italic>LTA</italic> locus is in linkage disequilibrium with <italic>HLA-DQB1</italic><xref ref-type="bibr" rid="pone.0002546-Li1">&#x0005b;21&#x0005d;</xref> and we have previously shown that the <italic>AGER</italic> -374T&#x02192;A polymorphism is associated with the <italic>HLA-DQB1</italic> risk genotypes <xref ref-type="bibr" rid="pone.0002546-Lindholm1">&#x0005b;13&#x0005d;</xref>. In a recent study the HLA 8.1 ancestral haplotype was shown to be strongly linked to the C allele of the <italic>AGER</italic> -429T&#x02192;C promoter polymorphism <xref ref-type="bibr" rid="pone.0002546-Laki1">&#x0005b;22&#x0005d;</xref>. Our aim was to study whether variants in these genes form a putative haplotype associated with increased risk of diabetic nephropathy, retinopathy and macrovascular disease.</p></sec><sec id="s2"><title>Results</title><p>Type 2 diabetic patients were older and had higher BMI than type 1 diabetic patients or non-diabetic controls (<xref ref-type="table" rid="pone-0002546-t001">Table 1</xref>). Genotype distributions of <italic>LTA</italic>, <italic>TNF</italic> and <italic>AGER</italic> polymorphisms are shown in <xref ref-type="table" rid="pone-0002546-t002">Table 2</xref>. All three variants deviated from the Hardy&#x02013;Weinberg equilibrium in type 1, but neither in type 2 diabetic patients nor in non-diabetic controls. In type 1 diabetic patients there was an excess of heterozygous patients with <italic>LTA</italic> (p&#x0003c;0.0002), <italic>TNF</italic> (p&#x0200a;&#x0003d;&#x0200a;0.02) and <italic>AGER</italic> (p&#x0200a;&#x0003d;&#x0200a;0.008). The genotype frequencies of the <italic>LTA</italic>, <italic>TNF</italic> and <italic>AGER</italic> polymorphisms were different between type 1 diabetic patients and controls and also between type 1 and type 2 diabetic patients. The <italic>LTA</italic>, <italic>TNF</italic> and <italic>AGER</italic> polymorphisms were associated with the <italic>HLA-DQB1</italic> genotypes (<xref ref-type="table" rid="pone-0002546-t003">Table 3</xref>). The minor allele (A) of the <italic>LTA</italic> polymorphism was less common in patients with than without <italic>HLA-DQB1</italic> genotypes risk genotypes (37.2 vs. 43.9&#x00025;, p&#x0200a;&#x0003d;&#x0200a;0.0001). No difference in allele frequencies of the <italic>TNF</italic> polymorphism was seen between patients with or without <italic>HLA-DQB1</italic> risk genotypes, however the minor allele (A) of the <italic>AGER</italic> polymorphism was more common in patients with than without <italic>HLA-DQB1</italic> risk alleles (34.5 vs. 22.9&#x00025;), p&#x0003c;0.000001). Because of lack of Hardy&#x02013;Weinberg equilibrium in type 1 diabetic patients, we could not confirm whether the <italic>LTA</italic>, <italic>TNF</italic> and <italic>AGER</italic> polymorphisms were in LD in type 1 diabetic patients. In type 2 diabetic patients and controls the LTA and <italic>TNF</italic> polymorphisms were in LD (D&#x02032;&#x0200a;&#x0003d;&#x0200a;1.00 &#x0005b;0.99&#x02013;1.00&#x0005d; , r<sup>2</sup>&#x0200a;&#x0003d;&#x0200a;0.4). The <italic>AGER</italic> polymorphism was neither in LD with <italic>LTA</italic> (D&#x02032; 0.13 &#x0005b;0.06&#x02013;0.20&#x0005d;, r<sup>2</sup>&#x0200a;&#x0003d;&#x0200a;0.004) nor with <italic>TNF</italic> (D&#x02032; 0.36 &#x0005b;0.23&#x02013;0.43&#x0005d;, r<sup>2</sup>&#x0200a;&#x0003d;&#x0200a;0.009) in type 2 diabetic patients.</p><table-wrap id="pone-0002546-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0002546.t001</object-id><label>Table 1</label><caption><title>Clinical characteristics of the patients and non-diabetic control subjects.</title></caption><graphic id="pone-0002546-t001-1" xlink:href="pone.0002546.t001"/><table frame="hsides" rules="groups" alternate-form-of="pone-0002546-t001-1"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Controls</td><td align="left" rowspan="1" colspan="1">Type 1</td><td align="left" rowspan="1" colspan="1">Type 2</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">N (M/F)</td><td align="left" rowspan="1" colspan="1">107/99</td><td align="left" rowspan="1" colspan="1">458/375</td><td align="left" rowspan="1" colspan="1">2240/1616</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (yrs.)</td><td align="left" rowspan="1" colspan="1">59.7&#x000b1;12.6<xref ref-type="table-fn" rid="nt101">a</xref></td><td align="left" rowspan="1" colspan="1">38.2&#x000b1;13.6</td><td align="left" rowspan="1" colspan="1">61.2&#x000b1;11.7<xref ref-type="table-fn" rid="nt102">b</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Age at diagnosis (yrs.)</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">18.2&#x000b1;9.1</td><td align="left" rowspan="1" colspan="1">55.6&#x000b1;12.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes duration (yrs.)</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">18.1&#x0005b;8.5&#x02013;29.6&#x0005d;</td><td align="left" rowspan="1" colspan="1">2.58&#x0005b;0.09&#x02013;9.54&#x0005d;</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="left" rowspan="1" colspan="1">25.8&#x000b1;3.8<xref ref-type="table-fn" rid="nt101">a</xref></td><td align="left" rowspan="1" colspan="1">23.8&#x000b1;3.1</td><td align="left" rowspan="1" colspan="1">29.7&#x000b1;5.6<xref ref-type="table-fn" rid="nt101">a</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">HbA<sub>1c</sub> (&#x00025;)</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">7.2&#x000b1;1.3</td><td align="left" rowspan="1" colspan="1">6.6&#x000b1;1.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Systolic BP (mmHg)</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">130.6&#x000b1;18.9</td><td align="left" rowspan="1" colspan="1">144.8&#x000b1;21.8</td></tr><tr><td align="left" rowspan="1" colspan="1">Diastolic BP (mmHg)</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">74.2&#x000b1;9.6</td><td align="left" rowspan="1" colspan="1">80.9&#x000b1;10.9</td></tr><tr><td align="left" rowspan="1" colspan="1">Smokers (current or previous)</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">51.5&#x00025;</td><td align="left" rowspan="1" colspan="1">61.1&#x00025;</td></tr></tbody></table><table-wrap-foot><fn id="nt101"><label>a</label><p>p&#x0003c;0.000001.</p></fn><fn id="nt102"><label>b</label><p>p&#x0200a;&#x0003d;&#x0200a;0.01. Type 1 and type 2 diabetic patients vs. controls.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone-0002546-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0002546.t002</object-id><label>Table 2</label><caption><title>Genotype frequencies (&#x00025;) of <italic>LTA</italic> T60N (C&#x02192;A), <italic>TNF</italic> -308 G&#x02192;A and <italic>AGER</italic> -374 T&#x02192;A polymorphism in nondiabetic controls and in type 1 and type 2 diabetic patients.</title></caption><graphic id="pone-0002546-t002-2" xlink:href="pone.0002546.t002"/><table frame="hsides" rules="groups" alternate-form-of="pone-0002546-t002-2"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Controls</td><td align="left" rowspan="1" colspan="1">Type 1</td><td align="left" rowspan="1" colspan="1">p</td><td align="left" rowspan="1" colspan="1">Corrected p</td><td align="left" rowspan="1" colspan="1">Type 2</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Corrected p</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><italic>LTA</italic> T60N (CC/CA/AA)</td><td align="left" rowspan="1" colspan="1">77/88/35 (38.5/44.0/17.5)</td><td align="left" rowspan="1" colspan="1">186/409/131 (25.6/56.3/18.0)</td><td align="left" rowspan="1" colspan="1">0.0003</td><td align="left" rowspan="1" colspan="1">0.05</td><td align="left" rowspan="1" colspan="1">1089/1395/436 (37.3/47.8/14.9)</td><td align="left" rowspan="1" colspan="1">0.73</td><td align="left" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>TNF</italic> -308 (GG/GA/AA)</td><td align="left" rowspan="1" colspan="1">133/66/6 (64.9/32.2/2.9)</td><td align="left" rowspan="1" colspan="1">350/329/50 (48.0/45.1/6.9)</td><td align="left" rowspan="1" colspan="1">0.00002</td><td align="left" rowspan="1" colspan="1">0.00009</td><td align="left" rowspan="1" colspan="1">1908/906/113 (65.2/31.0/3.9)</td><td align="left" rowspan="1" colspan="1">0.93</td><td align="left" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>AGER</italic> -374 (TT/TA/AA)</td><td align="left" rowspan="1" colspan="1">127/67/11 (62.0/32.7/5.4)</td><td align="left" rowspan="1" colspan="1">350/335/48 (47.7/45.7/6.5)</td><td align="left" rowspan="1" colspan="1">0.0003</td><td align="left" rowspan="1" colspan="1">0.007</td><td align="left" rowspan="1" colspan="1">1624/1108/198 (55.4/37.8/6.8)</td><td align="left" rowspan="1" colspan="1">0.07</td><td align="left" rowspan="1" colspan="1">0.31</td></tr></tbody></table><table-wrap-foot><fn id="nt103"><label/><p>The uncorrected p-value refers to differences in genotype frequencies (CC vs CA/AA, GG vs. GA/AA and TT vs. TA/AA). Corrected p-value refers to differences in allele frequencies after 100 000 permutations (haploview).</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone-0002546-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0002546.t003</object-id><label>Table 3</label><caption><title>Minor allele frequencies according to HLA-DQB1 genotype in type 1 diabetic patients.</title></caption><graphic id="pone-0002546-t003-3" xlink:href="pone.0002546.t003"/><table frame="hsides" rules="groups" alternate-form-of="pone-0002546-t003-3"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">LTA (A allele)<xref ref-type="table-fn" rid="nt105">a</xref></td><td align="left" rowspan="1" colspan="1">TNF (A allele)<xref ref-type="table-fn" rid="nt106">b</xref></td><td align="left" rowspan="1" colspan="1">AGER (A allele)<xref ref-type="table-fn" rid="nt107">c</xref></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">02/0301</td><td align="left" rowspan="1" colspan="1">26 (59.1)</td><td align="left" rowspan="1" colspan="1">17 (38.6)</td><td align="left" rowspan="1" colspan="1">5 (11.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">02/0302</td><td align="left" rowspan="1" colspan="1">214 (46.7)</td><td align="left" rowspan="1" colspan="1">174 (38.2)</td><td align="left" rowspan="1" colspan="1">131 (28.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">02/0602<xref ref-type="table-fn" rid="nt108">d</xref></td><td align="left" rowspan="1" colspan="1">2 (100.0)</td><td align="left" rowspan="1" colspan="1">1 (50.0)</td><td align="left" rowspan="1" colspan="1">1 (50.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">02/0603<xref ref-type="table-fn" rid="nt108">d</xref></td><td align="left" rowspan="1" colspan="1">6 (50.0)</td><td align="left" rowspan="1" colspan="1">5 (41.7)</td><td align="left" rowspan="1" colspan="1">2 (16.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">02/0604</td><td align="left" rowspan="1" colspan="1">26 (68.4)</td><td align="left" rowspan="1" colspan="1">13 (34.2)</td><td align="left" rowspan="1" colspan="1">2 (5.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">02/X</td><td align="left" rowspan="1" colspan="1">114 (67.1)</td><td align="left" rowspan="1" colspan="1">101 (58.7)</td><td align="left" rowspan="1" colspan="1">20 (11.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">0301/0302</td><td align="left" rowspan="1" colspan="1">29 (45.3)</td><td align="left" rowspan="1" colspan="1">13 (20.3)</td><td align="left" rowspan="1" colspan="1">28 (43.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">0301/0602<xref ref-type="table-fn" rid="nt108">d</xref></td><td align="left" rowspan="1" colspan="1">1 (50.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">2 (100.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">0301/0603<xref ref-type="table-fn" rid="nt108">d</xref></td><td align="left" rowspan="1" colspan="1">5 (83.3)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">1 (16.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">0301/0604<xref ref-type="table-fn" rid="nt108">d</xref></td><td align="left" rowspan="1" colspan="1">3 (50.0)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">1 (16.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">0301/X</td><td align="left" rowspan="1" colspan="1">9 (40.9)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">9 (40.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">0302/0602<xref ref-type="table-fn" rid="nt108">d</xref></td><td align="left" rowspan="1" colspan="1">1 (16.7)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">3 (37.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">0302/0603</td><td align="left" rowspan="1" colspan="1">33 (43.4)</td><td align="left" rowspan="1" colspan="1">6 (20.0)</td><td align="left" rowspan="1" colspan="1">14 (46.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">0302/0604</td><td align="left" rowspan="1" colspan="1">33 (43.4)</td><td align="left" rowspan="1" colspan="1">4 (5.1)</td><td align="left" rowspan="1" colspan="1">20 (26.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">0302/X</td><td align="left" rowspan="1" colspan="1">54 (22.7)</td><td align="left" rowspan="1" colspan="1">18 (7.5)</td><td align="left" rowspan="1" colspan="1">116 (48.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">0602/03/04/X<xref ref-type="table-fn" rid="nt108">d</xref></td><td align="left" rowspan="1" colspan="1">8 (42.9)</td><td align="left" rowspan="1" colspan="1">12 (14.3)</td><td align="left" rowspan="1" colspan="1">11 (21.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">0604/X</td><td align="left" rowspan="1" colspan="1">10 (50.0)</td><td align="left" rowspan="1" colspan="1">1 (5.0)</td><td align="left" rowspan="1" colspan="1">5 (25.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">X/X</td><td align="left" rowspan="1" colspan="1">9 (45.0)</td><td align="left" rowspan="1" colspan="1">2 (10.0)</td><td align="left" rowspan="1" colspan="1">8 (40.0)</td></tr></tbody></table><table-wrap-foot><fn id="nt104"><label/><p>Numbers are number of alleles N (&#x00025;).</p></fn><fn id="nt105"><label>a</label><p>P&#x0003c;0.000001, Chi-Square&#x0200a;&#x0003d;&#x0200a;94.2 df&#x0200a;&#x0003d;&#x0200a;11.</p></fn><fn id="nt106"><label>b</label><p>P&#x0003c;0.000001, Chi-Square&#x0200a;&#x0003d;&#x0200a;196.3,df&#x0200a;&#x0003d;&#x0200a;11.</p></fn><fn id="nt107"><label>c</label><p>P&#x0003c;0.000001, Chi-Square&#x0200a;&#x0003d;&#x0200a;98.8,df&#x0200a;&#x0003d;&#x0200a;11.</p></fn><fn id="nt108"><label>d</label><p>Expected value &#x0003c;5 in type 1 diabetes. These genotypes were pooled in the statistical analysis. X could mean either a homozygous allele or any allele other than 02, 0301, 0302, 0602 or 0604.</p></fn></table-wrap-foot></table-wrap><sec id="s2a"><title>Diabetic Nephropathy</title><p>Type 1 diabetic patients with diabetic nephropathy had a higher frequency of the <italic>RAGE</italic> -374 A allele (31.2&#x00025;) compared to those who maintained normoalbuminuria &#x02265;10 years (28.4&#x00025;) (P&#x0200a;&#x0003d;&#x0200a;0.007) (<xref ref-type="table" rid="pone-0002546-t004">Table 4</xref>) and the difference remained even after correction for multiple comparisons (p&#x0200a;&#x0003d;&#x0200a;0.02). The allele frequencies of <italic>TNF</italic> -308 G&#x02192;A and <italic>LTA</italic> T60N polymorphisms were similar in type 1 diabetic patients with and without diabetic nephropathy. No differences in allele or haplotype frequencies of the studied polymorphisms were observed between type 2 diabetic patients with and without diabetic nephropathy (<xref ref-type="table" rid="pone-0002546-t004">Table 4</xref>). In a logistic regression analysis with age, duration, BMI, HbA<sub>1c</sub>, systolic and diastolic blood pressure, sex, previous or current smoking and studied polymorphisms and <italic>HLA-DQB1</italic> risk genotypes as independent variables, having the <italic>LTA</italic> T60N A allele in type 1 diabetic patients was associated with increased risk diabetic nephropathy (OR 2.55&#x0005b;1.11&#x02013;5.86&#x0005d;,p&#x0200a;&#x0003d;&#x0200a;0.03), (<xref ref-type="fig" rid="pone-0002546-g001">Figure 1a</xref>). In type 2 diabetic patients, the <italic>HLA-DQB1</italic> risk allele but not <italic>LTA</italic>, <italic>TNF</italic> and <italic>AGER</italic> polymorphisms was associated with increased risk for diabetic nephropathy (1.75 &#x0005b;1.05&#x02013;2.94&#x0005d;, p&#x0200a;&#x0003d;&#x0200a;0.03). <italic>LTA</italic>, <italic>TNF</italic> and <italic>AGER</italic> polymorphisms were not associated with diabetic nephropathy in type 2 diabetic patients (<xref ref-type="fig" rid="pone-0002546-g001">Figure 1b</xref>).</p><fig id="pone-0002546-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0002546.g001</object-id><label>Figure 1</label><caption><title>Logistic regression analysis in type 1 (1a) and type 2 (1b) diabetic patients with <italic>LTA</italic> T60N (C&#x02192;A), <italic>TNF</italic> -308 G&#x02192;A, <italic>AGER</italic> -374 T&#x02192;A polymorphisms and <italic>HLA-DQB1</italic> risk genotypes as independent and diabetic complication as dependent variable.</title><p>Age, systolic and diastolic blood pressure, sex, previous/current smoking are included in all models. BMI is included in the models for nephropathy and macrovascular disease, duration in the models for nephropathy and retinopathy and age at diagnosis in the model for macrovascular disease.</p></caption><graphic xlink:href="pone.0002546.g001"/></fig><table-wrap id="pone-0002546-t004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0002546.t004</object-id><label>Table 4</label><caption><title>Allelic association of <italic>LTA</italic> T60N (C&#x02192;A), <italic>TNF</italic> -308G&#x02192;A and <italic>AGER</italic> -374 T&#x02192;A polymorphism with diabetic nephropathy, retinopathy and macrovascular complications.</title></caption><graphic id="pone-0002546-t004-4" xlink:href="pone.0002546.t004"/><table frame="hsides" rules="groups" alternate-form-of="pone-0002546-t004-4"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td colspan="4" align="left" rowspan="1">Type 1</td><td colspan="4" align="left" rowspan="1">Type 2</td></tr></thead><tbody><tr><td colspan="10" align="left" rowspan="1"><bold>NEPHROPATHY</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">p</td><td align="left" rowspan="1" colspan="1">corrected p</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">p</td><td align="left" rowspan="1" colspan="1">corrected p</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>LTA</italic> T60N C&#x02192;A</td><td align="left" rowspan="1" colspan="1">Controls</td><td align="left" rowspan="1" colspan="1">340</td><td align="left" rowspan="1" colspan="1">27.9/53.2/18.9</td><td align="left" rowspan="1" colspan="1">0.317</td><td align="left" rowspan="1" colspan="1">0.918</td><td align="left" rowspan="1" colspan="1">442</td><td align="left" rowspan="1" colspan="1">33.3/47.3/19.5</td><td align="left" rowspan="1" colspan="1">0.205</td><td align="left" rowspan="1" colspan="1">0.592</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Cases</td><td align="left" rowspan="1" colspan="1">113</td><td align="left" rowspan="1" colspan="1">18.6/63.7/17.7</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">314</td><td align="left" rowspan="1" colspan="1">37.2/45.9/16.9</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>TNF</italic> -308 G&#x02192;A</td><td align="left" rowspan="1" colspan="1">Controls</td><td align="left" rowspan="1" colspan="1">342</td><td align="left" rowspan="1" colspan="1">47.7/46.5/5.8</td><td align="left" rowspan="1" colspan="1">0.503</td><td align="left" rowspan="1" colspan="1">0.983</td><td align="left" rowspan="1" colspan="1">438</td><td align="left" rowspan="1" colspan="1">63.9/30.4/5.7</td><td align="left" rowspan="1" colspan="1">0.559</td><td align="left" rowspan="1" colspan="1">0.970</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Cases</td><td align="left" rowspan="1" colspan="1">113</td><td align="left" rowspan="1" colspan="1">44.2/48.7/7.1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">314</td><td align="left" rowspan="1" colspan="1">65.0/30.9/4.1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>AGER</italic> -374 T&#x02192;A</td><td align="left" rowspan="1" colspan="1">Controls</td><td align="left" rowspan="1" colspan="1">345</td><td align="left" rowspan="1" colspan="1">52.2/41.2/6.7</td><td align="left" rowspan="1" colspan="1">0.007</td><td align="left" rowspan="1" colspan="1">0.023</td><td align="left" rowspan="1" colspan="1">439</td><td align="left" rowspan="1" colspan="1">54.2/37.6/8.2</td><td align="left" rowspan="1" colspan="1">0.119</td><td align="left" rowspan="1" colspan="1">0.509</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Cases</td><td align="left" rowspan="1" colspan="1">114</td><td align="left" rowspan="1" colspan="1">34.2/57.9/7.9</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">315</td><td align="left" rowspan="1" colspan="1">58.1/37.1/4.8</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="10" align="left" rowspan="1"><bold>RETINOPATHY</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>LTA</italic> T60N C&#x02192;A</td><td align="left" rowspan="1" colspan="1">Controls</td><td align="left" rowspan="1" colspan="1">310</td><td align="left" rowspan="1" colspan="1">29.4/53.5/17.1</td><td align="left" rowspan="1" colspan="1">0.154</td><td align="left" rowspan="1" colspan="1">0.461</td><td align="left" rowspan="1" colspan="1">584</td><td align="left" rowspan="1" colspan="1">34.1/49.8/16.1</td><td align="left" rowspan="1" colspan="1">0.608</td><td align="left" rowspan="1" colspan="1">0.986</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Cases</td><td align="left" rowspan="1" colspan="1">310</td><td align="left" rowspan="1" colspan="1">21.6/60.6/17.7</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">296</td><td align="left" rowspan="1" colspan="1">37.5/45.6/16.9</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>TNF</italic> -308 G&#x02192;A</td><td align="left" rowspan="1" colspan="1">Controls</td><td align="left" rowspan="1" colspan="1">307</td><td align="left" rowspan="1" colspan="1">50.2/43.6/6.2</td><td align="left" rowspan="1" colspan="1">0.573</td><td align="left" rowspan="1" colspan="1">0.982</td><td align="left" rowspan="1" colspan="1">583</td><td align="left" rowspan="1" colspan="1">65.0/30.7/4.3</td><td align="left" rowspan="1" colspan="1">0.368</td><td align="left" rowspan="1" colspan="1">0.878</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Cases</td><td align="left" rowspan="1" colspan="1">315</td><td align="left" rowspan="1" colspan="1">46.0/48.9/5.1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">295</td><td align="left" rowspan="1" colspan="1">67.8/28.8/3.4</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>AGER</italic> -374 T&#x02192;A</td><td align="left" rowspan="1" colspan="1">Controls</td><td align="left" rowspan="1" colspan="1">313</td><td align="left" rowspan="1" colspan="1">48.9/45.3/5.8</td><td align="left" rowspan="1" colspan="1">0.295</td><td align="left" rowspan="1" colspan="1">0.774</td><td align="left" rowspan="1" colspan="1">583</td><td align="left" rowspan="1" colspan="1">54.9/36.5/8.6</td><td align="left" rowspan="1" colspan="1">0.734</td><td align="left" rowspan="1" colspan="1">0.998</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Cases</td><td align="left" rowspan="1" colspan="1">315</td><td align="left" rowspan="1" colspan="1">44.8/47.9/7.3</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">298</td><td align="left" rowspan="1" colspan="1">50.3/44.0/5.7</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="10" align="left" rowspan="1"><bold>MACROVASCULAR COMPLICATIONS</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>LTA</italic> T60N C&#x02192;A</td><td align="left" rowspan="1" colspan="1">Controls</td><td align="left" rowspan="1" colspan="1">609</td><td align="left" rowspan="1" colspan="1">27.6/55.2/17.2</td><td align="left" rowspan="1" colspan="1">0.034</td><td align="left" rowspan="1" colspan="1">0.122</td><td align="left" rowspan="1" colspan="1">1802</td><td align="left" rowspan="1" colspan="1">38.1/47.5/14.4</td><td align="left" rowspan="1" colspan="1">0.102</td><td align="left" rowspan="1" colspan="1">0.456</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Cases</td><td align="left" rowspan="1" colspan="1">112</td><td align="left" rowspan="1" colspan="1">15.2/64.3/20.5</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">885</td><td align="left" rowspan="1" colspan="1">35.0/48.6/16.4</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>TNF</italic> -308 G&#x02192;A</td><td align="left" rowspan="1" colspan="1">Controls</td><td align="left" rowspan="1" colspan="1">611</td><td align="left" rowspan="1" colspan="1">49.3/44.0/6.7</td><td align="left" rowspan="1" colspan="1">0.426</td><td align="left" rowspan="1" colspan="1">0.916</td><td align="left" rowspan="1" colspan="1">1804</td><td align="left" rowspan="1" colspan="1">67.3/29.2/3.5</td><td align="left" rowspan="1" colspan="1">0.003</td><td align="left" rowspan="1" colspan="1">0.017</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Cases</td><td align="left" rowspan="1" colspan="1">113</td><td align="left" rowspan="1" colspan="1">42.5/52.2/5.3</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">886</td><td align="left" rowspan="1" colspan="1">61.4/34.1/4.5</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>AGER</italic> -374 T&#x02192;A</td><td align="left" rowspan="1" colspan="1">Controls</td><td align="left" rowspan="1" colspan="1">617</td><td align="left" rowspan="1" colspan="1">48.8/44.6/6.6</td><td align="left" rowspan="1" colspan="1">0.299</td><td align="left" rowspan="1" colspan="1">0.797</td><td align="left" rowspan="1" colspan="1">1809</td><td align="left" rowspan="1" colspan="1">54.4/38.1/7.5</td><td align="left" rowspan="1" colspan="1">0.010</td><td align="left" rowspan="1" colspan="1">0.052</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Cases</td><td align="left" rowspan="1" colspan="1">111</td><td align="left" rowspan="1" colspan="1">41.4/52.3/6.3</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">888</td><td align="left" rowspan="1" colspan="1">58.8/35.9/5.3</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="nt109"><label/><p>The uncorrected p-value refers to differences in allele frequencies. Corrected p-value refers to differences in allele frequencies using after 100 000 permutations (Haploview).</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2b"><title>Diabetic retinopathy</title><p>The allele (or haplotype) frequencies of the studied polymorphisms did not differ between patients with and without sight-threatening retinopathy, neither in type 1 nor in type 2 diabetic patients (<xref ref-type="table" rid="pone-0002546-t004">Table 4</xref>). In a logistic regression analysis with age, duration, HbA<sub>1c</sub>, systolic and diastolic blood pressure, sex, current/previous smoking and genotypes as independent variables, <italic>HLA-DQB1</italic> risk genotype was associated with decreased risk for sight-threatening retinopathy in type 1 diabetic patients (0.66&#x0005b;0.44&#x02013;0.99&#x0005d;, p&#x0200a;&#x0003d;&#x0200a;0.04). In contrast <italic>LTA</italic>, <italic>TNF</italic> and <italic>AGER</italic> polymorphisms were not associated with sight-threatening retinopathy in type 1 diabetic patients (<xref ref-type="fig" rid="pone-0002546-g001">Figure 1a</xref>). In type 2 diabetic patients the <italic>AGER</italic> A allele was associated with increased risk for sight-threatening retinopathy (1.65&#x0005b;1.11&#x02013;2.45&#x0005d;, p&#x0200a;&#x0003d;&#x0200a;0.01) (<xref ref-type="fig" rid="pone-0002546-g001">Figure 1b</xref>).</p></sec><sec id="s2c"><title>Macrovascular complications</title><p>Type 1 diabetic patients with a history of macrovascular complications had higher frequency of the <italic>LTA</italic> A allele than patients without macrovascular complications (52.7&#x00025; vs. 44.8&#x00025;, p&#x0200a;&#x0003d;&#x0200a;0.03) (<xref ref-type="table" rid="pone-0002546-t004">Table 4</xref>). The allele frequencies of the <italic>TNF</italic> and <italic>AGER</italic> polymorphisms did not differ between type 1 diabetic patients with and without history of macrovascular disease.</p><p>In a logistic regression analysis, the <italic>AGER</italic> &#x02013; 374 A allele was associated with increased risk for macrovascular complications (OR 2.05&#x0005b;1.19&#x02013;3.54&#x0005d;, p&#x0200a;&#x0003d;&#x0200a;0.01), <xref ref-type="fig" rid="pone-0002546-g001">Figure 1a</xref>) in type 1 diabetic patients. The <italic>HLA-DQB1</italic> risk genotype was associated with decreased risk for macrovascular disease in type 1 diabetic patients (OR 0.49&#x0005b;0.28&#x02013;0.86&#x0005d;, p&#x0200a;&#x0003d;&#x0200a;0.01). The gene-gene interaction was tested in a separate logistic regression model (assuming a dominant model) by adding a term (AGER)&#x000d7;(HLA risk genotype). The gene-gene interaction term was however not significant and was therefore not included in the final model (<xref ref-type="fig" rid="pone-0002546-g001">Figure 1a</xref>).</p><p>In type 2 diabetic patients the frequency of both <italic>TNF</italic> -308 A allele and <italic>AGER</italic> -374 T allele genotype was higher in patients with than without macrovascular complications (21.6&#x00025; vs. 18.1&#x00025;, p&#x0200a;&#x0003d;&#x0200a;0.003 and 76.7&#x00025; vs. 73.5&#x00025;, p&#x0200a;&#x0003d;&#x0200a;0.03, respectively) (<xref ref-type="table" rid="pone-0002546-t004">Table 4</xref>), the significance of difference in frequency of AGER -374 polymorphism did not stand multiple comparisons (<xref ref-type="table" rid="pone-0002546-t004">Table 4</xref>). The AA haplotype of <italic>TNF</italic> and <italic>LTA</italic> was more common in type 2 diabetic patients with than without macrovascular disease (21.5&#x00025; vs. 18.1&#x00025;, p&#x0200a;&#x0003d;&#x0200a;0.003). In a logistic regression analysis the <italic>TNF</italic> -308 A allele (OR 1.53&#x0005b;1.04&#x02013;2.25&#x0005d;, p&#x0200a;&#x0003d;&#x0200a;0.03) was associated with increased and the <italic>AGER</italic> -374 A allele with decreased risk (OR 0.66&#x0005b;0.49&#x02013;0.90&#x0005d;, p&#x0200a;&#x0003d;&#x0200a;0.009) for macrovascular disease (<xref ref-type="fig" rid="pone-0002546-g001">Figure 1b</xref>). The gene-gene interaction was tested in a separate logistic regression model (assuming a dominant model) by adding a term (AGER)&#x000d7;(TNF). The gene-gene interaction term was however not significant and was therefore not included in the final model (<xref ref-type="fig" rid="pone-0002546-g001">Figure 1b</xref>).</p></sec></sec><sec id="s3"><title>Discussion</title><p>The key finding of the present study was that the polymorphisms in the <italic>TNF</italic>, <italic>LTA</italic> and <italic>AGER</italic> genes were associated with high risk <italic>HLA-DQB1</italic> alleles on chromosome 6p21 and that they influenced the risk for late diabetic complications. The <italic>TNF</italic>, <italic>LTA</italic> and <italic>AGER</italic> alleles were in Hardy-Weinberg equilibrium in as well in non-diabetic controls as in type 2 diabetic patients. In type 1 diabetic patients all of the studied polymorphisms deviated from Hardy-Weinberg equilibrium having excess of heterozygous alleles. This is well in line with previous observations of a synergistic effect of the DR3 and DR4 haplotypes DRB1&#x0002a;0301-DQA1&#x0002a;0501-DQB1&#x0002a;0201 and DRB1&#x0002a;0401-DQA1&#x0002a;0301-DQB1&#x0002a;0302 which are strongly associated with type 1 diabetes thus leading to excess of heterozygous versus homozygous patients <xref ref-type="bibr" rid="pone.0002546-Noble1">&#x0005b;23&#x0005d;</xref>. Deviation from Hardy-Weinberg equilibrium will influence the estimated haplotype frequencies especially in a situation with excess of homozygous patients <xref ref-type="bibr" rid="pone.0002546-Single1">&#x0005b;24&#x0005d;</xref>. Therefore, we could not test whether <italic>LTA</italic>, <italic>TNF</italic> and <italic>AGER</italic> polymorphisms are in linkage disequilibrium in type 1 diabetic patients as suggested by Laki et. al. who recently showed that the HLA 8.1 ancestral haplotype (8.1 AH) was strongly linked to the <italic>AGER</italic> -429T&#x02192;C polymorphism and the AGER -429 allele should therefore be considered as candidate member of the HLA 8.1 ancestral haplotype <xref ref-type="bibr" rid="pone.0002546-Laki1">&#x0005b;22&#x0005d;</xref>.</p><p>The association patterns between diabetic complications and polymorphisms in <italic>LTA</italic>, <italic>TNF</italic>, <italic>AGER</italic> and <italic>HLA</italic> was complex and none of the studied polymorphism was associated with all diabetic complications in either type 1 or type 2 diabetic patients. For example, the A allele of the <italic>AGER</italic> -374 polymorphism was more common in type 1 diabetic patients with than without diabetic nephropathy. In a regression model however, when all of the polymorphisms and <italic>HLA-DQB1</italic> risk genotype were included in the model, <italic>LTA</italic> rather than <italic>AGER</italic> was a risk factor for diabetic nephropathy in type 1 diabetic patients. Similarly, the <italic>AGER</italic> A allele was associated with increased risk for sight-threatening retinopathy but decreased risk for macrovascular disease in type 2 diabetic patients which raises a question, whether this could represent a survival bias because of the strong association between <italic>TNF</italic> and <italic>AGER</italic> polymorphisms and macrovascular disease.</p><p>The lack of association in type 1 diabetic patients could of course be due to small sample size. Another possible source of bias could be population stratification due to ethically diverse samples, which is not very likely given the fact that all patients were Scandinavians. Previous studies on the putative association between polymorphisms in the <italic>LTA</italic>, <italic>TNF</italic> and <italic>RAGE</italic> genes and micro-and macrovascular complications in type 2 diabetes have given conflicting results <xref ref-type="bibr" rid="pone.0002546-PetterssonFernholm1">&#x0005b;14&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0002546-Asselbergs1">&#x0005b;20&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002546-Hudson1">&#x0005b;25&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0002546-Zeggini1">&#x0005b;30&#x0005d;</xref>. Differences in study design, insufficient power and inclusion of different ethnic groups might explain some of the observed differences, as would inclusion of type 2 diabetic patients with LADA <xref ref-type="bibr" rid="pone.0002546-Zeggini1">&#x0005b;30&#x0005d;</xref>. To circumvent this problem we excluded adult patients who were GAD antibody positive or required insulin therapy during the first year.</p><p>Some of the discrepancy in the published literature could also be due to the complex pattern of LD in the region. The HLA region on the short arm of chromosome 6 contains several genes involved in inflammatory responses. The haplotypic structure is complex and there is also a complex interaction between genes and gene products, as illustrated by the <italic>TNF</italic> gene polymorphism that can influence transcription of LTA <xref ref-type="bibr" rid="pone.0002546-Knight1">&#x0005b;8&#x0005d;</xref>, and receptor for advanced glycation end-products (RAGE), which after binding to its ligand can increase production of pro-inflammatory cytokines, among them TNF-&#x003b1; <xref ref-type="bibr" rid="pone.0002546-Yeh1">&#x0005b;31&#x0005d;</xref>.</p><p>Taken together the data show that polymorphisms in the <italic>LTA</italic>, <italic>TNF and AGER</italic> genes increase risk of diabetic micro- and macroangiopathy either alone or together. Given the strong association with HLA-risk genotypes we can not rule out that they are part of a same haplotype and their risk on disease can therefore only be judged from studies assessing them all.</p></sec><sec sec-type="materials|methods" id="s4"><title>Materials and Methods</title><p>A detailed description of study subjects and analytical methods has been given previously <xref ref-type="bibr" rid="pone.0002546-Lindholm1">&#x0005b;13&#x0005d;</xref>. The study population was mainly the same as in the previous study. However, additional 98 type 1 and 796 type 2 diabetic patients were included and genotyped for the <italic>AGER</italic> -374T&#x02192;A polymorphism in this study and all the patients were also genotyped for the <italic>TNF</italic> -308 G&#x02192;A and <italic>LTA</italic> T60N C&#x02192;A polymorphisms. Patients were classified as having type 1 or type 2 diabetes by the attending physician using the World Health Organization (WHO) guidelines of 1985 <xref ref-type="bibr" rid="pone.0002546-Noble1">&#x0005b;23&#x0005d;</xref> or, when diagnosed after January 1, 2001, according to the new WHO guidelines <xref ref-type="bibr" rid="pone.0002546-Single1">&#x0005b;24&#x0005d;</xref>. Type 1 diabetic patients with age at onset &#x0003e;35 years (N&#x0200a;&#x0003d;&#x0200a;224) and type 2 diabetic patients positive for GAD antibodies (N&#x0200a;&#x0003d;&#x0200a;197) were excluded. In addition, type 2 diabetic patients with an age at diagnosis &#x0003c;35 years and with permanent insulin treatment during the first year from diagnosis were excluded (N&#x0200a;&#x0003d;&#x0200a;108). A total of 3699 (742 type 1 and 2957 type 2 diabetes) Scandinavian patients and 206 Scandinavian, non-diabetic control subjects were included in the study. Control subjects were selected among spouses of patients with hypertension; they were not allowed to have any first degree relatives with diabetes. No information on hypertension or myocardial infarction in non-diabetic control subjects was available. The Ethics committee of Malm&#x000f6;/Lund approved the study. Informed consent was obtained from all patients.</p><sec id="s4a"><title>Assessment of complications</title><sec id="s4a1"><title>Diabetic nephropathy</title><p>The urinary albumin concentration was determined by immunonephelometry (Beckman Instruments, CA, USA) until 1998 and thereafter by an immunoturbimetric method (Beckman Coulter, Beckman Instruments, CA, USA). Albuminuria was reported either as &#x000b5;g/min (AER), mg/24 hours or as a urinary albumin/creatinine ratio (g/mol). Microalbuminuria was defined as 20&#x02013;200 &#x000b5;g/min, 30&#x02013;300 mg/24 hours or 2.0&#x02013;25 in males and 2.8&#x02013;25 g/mol in females. For the definition of microalbuminuria we also considered older values given as the urinary albumin concentration measured in a first morning specimen. Values of 30&#x02013;300 mg/l were considered as microalbuminuria. Values above the upper limit were indicative of macroalbuminuria. Macroalbuminuria was considered present when at least two values above the cut-off limit for macroalbuminuria were recorded. One positive measurement only was considered as macroalbuminuria if the patient thereafter was treated with ACE inhibitors or angiotensin II receptor blockers or if the patient had had persistent microalbuminuria previously. Patients with other kidney diseases were excluded from the analysis. Normoalbuminuria required that all urinary albumin measurements were within the normal range, otherwise the albuminuria status was considered unknown. Duration of albuminuria was calculated from the onset of microalbuminuria when known, or from the latest measurement with no albuminuria. If not known (60&#x00025; of all the cases with micro- or macroalbuminuria, 39&#x00025; in type 1 diabetic patients) the duration was calculated from the first registered value of micro- or macroalbuminuria. When calculating the genotype frequencies in patients with normoalbuminuria, only patients with diabetes duration &#x02265;10 years were included.</p></sec><sec id="s4a2"><title>Diabetic Retinopathy</title><p>Information about the retinopathy status was available in 3072 patients. Patients were divided into two groups; subjects with no or non-proliferative retinopathy without macular edema and subjects with sight-threatening retinopathy, which included patients with proliferative retinopathy and/or photocoagulation treatment (panretinal and/or focal/grid for macular edema). The duration of sight-threatening retinopathy was defined from the first information of diagnosis or laser treatment. When calculating the genotype frequencies in patients without sight-threatening retinopathy only those with diabetes duration &#x02265;10 years were included.</p></sec><sec id="s4a3"><title>Macrovascular disease</title><p>Macrovascular disease was defined as previously diagnosed myocardial infarction, angina pectoris, transitory ischemic attack (TIA), stroke and/or peripheral vascular disease. Information on previous macrovascular disease was available in 93&#x00025; of the patients.</p><p>In logistic regression analysis age at diagnosis was used in stead of duration because the macrovascular disease duration was often unknown and sometimes a decade before the onset of diabetes. Lipid levels were not used in the regression analysis, because according to the clinical guidelines patients with previous episode of myocardial infarction or stroke should be treated with statins. Consequently, current cholesterol levels were lower in patients with previous episode of macrovascular disease and we did not have access to historical data.</p></sec></sec><sec id="s4b"><title>Genotyping</title><p>T60N C&#x02192;A (rs1041981), <italic>TNF</italic> -308 G&#x02192;A (rs1800629), and <italic>AGER</italic> -374 T&#x02192;A (rs1800624) polymorphisms were genotyped using the allelic discrimination method on the ABI 7900 instrument (Applied Biosystems, Foster City, CA). A subset of patient (629 type 1 and 1108 type 2 diabetic patients and all control subjects were previously genotyped for <italic>HLA-DQB1</italic><xref ref-type="bibr" rid="pone.0002546-Lindholm1">&#x0005b;13&#x0005d;</xref>. The genotyping success rates were 99.0&#x00025; for the <italic>LTA</italic>, 98.7&#x00025; for the <italic>TNF</italic> and 98.4&#x00025; for the <italic>AGER</italic> polymorphisms. Re-genotyping was performed in a separate analysis in random samples from those which passed. A total of 226 (<italic>LTA</italic>), 234 (<italic>TNF</italic>) and 225 (<italic>AGER</italic>) patients were re-genotyped with a 100&#x00025; genotyping concordance rate.</p></sec><sec id="s4c"><title>Statistical analysis</title><p>Data are presented as mean&#x000b1;SD or as median and interquartile range &#x0005b;25<sup>th</sup>&#x02013;75<sup>th</sup>&#x0005d;. Chi-square test was used to test for frequency differences between studied genotypes. To test differences between group means, the Student's two-tailed t-test was used for normally distributed values and Mann-Whitney U-test for non-normally distributed medians. In order to assess factors associated with diabetic nephropathy, retinopathy and macrovascular disease, a multiple logistic regression analysis with forward selection was performed. All data were analysed with a NCSS 2004 (NCSS statistical software, Kaysville, UT, USA). A p-value &#x0003c;0.05 was considered statistically significant. To evaluate putative haplotype blocks, linkage disequilibrium (LD) between the SNPs was analyzed using Haploview 3.32 and D&#x02032; values were calculated with 95&#x00025; confidence intervals (CI) when the genotype frequencies were in Hardy-Weinberg equilibrium <xref ref-type="bibr" rid="pone.0002546-Barrett1">&#x0005b;32&#x0005d;</xref>. A corrected p-value was obtained after 100,000 permutations of individual SNPs and haplotype blocks including the <italic>TNF</italic>, <italic>LTA</italic> and <italic>AGER</italic> polymorphisms. Power analysis was made using Genetic Power calculator <xref ref-type="bibr" rid="pone.0002546-Purcell1">&#x0005b;33&#x0005d;</xref>. HW-QuickCheck software <xref ref-type="bibr" rid="pone.0002546-Kalinowski1">&#x0005b;34&#x0005d;</xref> was used for testing of putative excess of heterozygous/ homozygous patients.</p><sec id="s4c1"><title>Power calculations</title><p>Power assuming &#x003b1;&#x0200a;&#x0003d;&#x0200a;0.05 and relative risk of 1.3 was 11&#x00025;, 31&#x00025; and 32&#x00025; for type 1 diabetic patients and 62&#x00025;, 81&#x00025; and 80&#x00025; for type 2 diabetic patients with or without diabetic nephropathy for the <italic>LTA</italic>, <italic>TNF</italic> and <italic>AGER</italic> polymorphisms. The power for retinopathy was 68&#x00025;, 86&#x00025; and 85&#x00025; in type 1 and 58&#x00025;, 73&#x00025; and 73&#x00025; in type 2 diabetes and for macrovascular disease 20&#x00025;, 28&#x00025; and 28&#x00025; in type 1 and 97&#x00025;, 99&#x00025; and 99&#x00025; in type 2 diabetes.</p></sec></sec></sec></body><back><ref-list><title>References</title><ref id="pone.0002546-Navarro1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Navarro</surname><given-names>JF</given-names></name><name><surname>Mora</surname><given-names>C</given-names></name></person-group><year>2005</year><article-title>Role of inflammation in diabetic complications.</article-title><source>Nephrol Dial Transplant</source><volume>20</volume><fpage>2601</fpage><lpage>2604</lpage><pub-id pub-id-type="pmid">16188894</pub-id></citation></ref><ref id="pone.0002546-Joussen1"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Joussen</surname><given-names>AM</given-names></name><name><surname>Poulaki</surname><given-names>V</given-names></name><name><surname>Tsujikawa</surname><given-names>A</given-names></name><name><surname>Qin</surname><given-names>W</given-names></name><name><surname>Qaum</surname><given-names>T</given-names></name><etal/></person-group><year>2002</year><article-title>Suppression of diabetic retinopathy with angiopoietin-1.</article-title><source>Am J Pathol</source><volume>160</volume><fpage>1683</fpage><lpage>1693</lpage><pub-id pub-id-type="pmid">12000720</pub-id></citation></ref><ref id="pone.0002546-Joussen2"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Joussen</surname><given-names>AM</given-names></name><name><surname>Poulaki</surname><given-names>V</given-names></name><name><surname>Le</surname><given-names>ML</given-names></name><name><surname>Koizumi</surname><given-names>K</given-names></name><name><surname>Esser</surname><given-names>C</given-names></name><etal/></person-group><year>2004</year><article-title>A central role for inflammation in the pathogenesis of diabetic retinopathy.</article-title><source>Faseb J</source><volume>18</volume><fpage>1450</fpage><lpage>1452</lpage><pub-id pub-id-type="pmid">15231732</pub-id></citation></ref><ref id="pone.0002546-Gustavsson1"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gustavsson</surname><given-names>C</given-names></name><name><surname>Agardh</surname><given-names>CD</given-names></name><name><surname>Bengtsson</surname><given-names>B</given-names></name><name><surname>Agardh</surname><given-names>E</given-names></name></person-group><year>2007</year><article-title>TNF-alpha is an independent serum marker for proliferative retinopathy in type 1 diabetic patients.</article-title><source>Journal of Diabetes and Its Complications (In Press)</source></citation></ref><ref id="pone.0002546-DallaVestra1"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dalla Vestra</surname><given-names>M</given-names></name><name><surname>Mussap</surname><given-names>M</given-names></name><name><surname>Gallina</surname><given-names>P</given-names></name><name><surname>Bruseghin</surname><given-names>M</given-names></name><name><surname>Cernigoi</surname><given-names>AM</given-names></name><etal/></person-group><year>2005</year><article-title>Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes.</article-title><source>J Am Soc Nephrol</source><volume>16</volume><issue>Suppl 1</issue><fpage>S78</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">15938041</pub-id></citation></ref><ref id="pone.0002546-Libby1"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Libby</surname><given-names>P</given-names></name><name><surname>Theroux</surname><given-names>P</given-names></name></person-group><year>2005</year><article-title>Pathophysiology of coronary artery disease.</article-title><source>Circulation</source><volume>111</volume><fpage>3481</fpage><lpage>3488</lpage><pub-id pub-id-type="pmid">15983262</pub-id></citation></ref><ref id="pone.0002546-Makhatadze1"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Makhatadze</surname><given-names>NJ</given-names></name></person-group><year>1998</year><article-title>Tumor necrosis factor locus: genetic organisation and biological implications.</article-title><source>Hum Immunol</source><volume>59</volume><fpage>571</fpage><lpage>579</lpage><pub-id pub-id-type="pmid">9757913</pub-id></citation></ref><ref id="pone.0002546-Knight1"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Knight</surname><given-names>JC</given-names></name><name><surname>Keating</surname><given-names>BJ</given-names></name><name><surname>Rockett</surname><given-names>KA</given-names></name><name><surname>Kwiatkowski</surname><given-names>DP</given-names></name></person-group><year>2003</year><article-title>In vivo characterization of regulatory polymorphisms by allele-specific quantification of RNA polymerase loading.</article-title><source>Nat Genet</source><volume>33</volume><fpage>469</fpage><lpage>475</lpage><pub-id pub-id-type="pmid">12627232</pub-id></citation></ref><ref id="pone.0002546-Vlassara1"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vlassara</surname><given-names>H</given-names></name><name><surname>Palace</surname><given-names>MR</given-names></name></person-group><year>2003</year><article-title>Glycoxidation: the menace of diabetes and aging.</article-title><source>Mt Sinai J Med</source><volume>70</volume><fpage>232</fpage><lpage>241</lpage><pub-id pub-id-type="pmid">12968196</pub-id></citation></ref><ref id="pone.0002546-Dyck1"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dyck</surname><given-names>R</given-names></name><name><surname>Bohm</surname><given-names>C</given-names></name><name><surname>Klomp</surname><given-names>H</given-names></name></person-group><year>2003</year><article-title>Increased frequency of HLA A2/DR4 and A2/DR8 haplotypes in young saskatchewan aboriginal people with diabetic end-stage renal disease.</article-title><source>Am J Nephrol</source><volume>23</volume><fpage>178</fpage><lpage>185</lpage><pub-id pub-id-type="pmid">12700434</pub-id></citation></ref><ref id="pone.0002546-Agardh1"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Agardh</surname><given-names>D</given-names></name><name><surname>Gaur</surname><given-names>LK</given-names></name><name><surname>Agardh</surname><given-names>E</given-names></name><name><surname>Landin-Olsson</surname><given-names>M</given-names></name><name><surname>Agardh</surname><given-names>CD</given-names></name><etal/></person-group><year>1996</year><article-title>HLA-DQB1&#x0002a;0201/0302 is associated with severe retinopathy in patients with IDDM.</article-title><source>Diabetologia</source><volume>39</volume><fpage>1313</fpage><lpage>1317</lpage><pub-id pub-id-type="pmid">8932997</pub-id></citation></ref><ref id="pone.0002546-Dahlen1"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dahlen</surname><given-names>GH</given-names></name><name><surname>Slunga</surname><given-names>L</given-names></name><name><surname>Holmlund</surname><given-names>G</given-names></name><name><surname>Lango</surname><given-names>A</given-names></name><name><surname>Lindblom</surname><given-names>B</given-names></name></person-group><year>1993</year><article-title>Lp(a) lipoprotein and HLA-DR genotype in early coronary artery disease.</article-title><source>Eur J Immunogenet</source><volume>20</volume><fpage>95</fpage><lpage>102</lpage><pub-id pub-id-type="pmid">8494873</pub-id></citation></ref><ref id="pone.0002546-Lindholm1"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lindholm</surname><given-names>E</given-names></name><name><surname>Bakhtadze</surname><given-names>E</given-names></name><name><surname>Sjogren</surname><given-names>M</given-names></name><name><surname>Cilio</surname><given-names>CM</given-names></name><name><surname>Agardh</surname><given-names>E</given-names></name><etal/></person-group><year>2006</year><article-title>The -374 T/A polymorphism in the gene encoding RAGE is associated with diabetic nephropathy and retinopathy in type 1 diabetic patients.</article-title><source>Diabetologia</source><volume>49</volume><fpage>2745</fpage><lpage>2755</lpage><pub-id pub-id-type="pmid">16969646</pub-id></citation></ref><ref id="pone.0002546-PetterssonFernholm1"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pettersson-Fernholm</surname><given-names>K</given-names></name><name><surname>Forsblom</surname><given-names>C</given-names></name><name><surname>Hudson</surname><given-names>BI</given-names></name><name><surname>Perola</surname><given-names>M</given-names></name><name><surname>Grant</surname><given-names>PJ</given-names></name><etal/></person-group><year>2003</year><article-title>The functional -374 T/A RAGE gene polymorphism is associated with proteinuria and cardiovascular disease in type 1 diabetic patients.</article-title><source>Diabetes</source><volume>52</volume><fpage>891</fpage><lpage>894</lpage><pub-id pub-id-type="pmid">12606536</pub-id></citation></ref><ref id="pone.0002546-Manchanda1"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Manchanda</surname><given-names>PK</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Kaul</surname><given-names>A</given-names></name><name><surname>Mittal</surname><given-names>RD</given-names></name></person-group><year>2006</year><article-title>Correlation between a gene polymorphism of tumor necrosis factor-alpha (G/A) and end-stage renal disease: a pilot study from north India.</article-title><source>Clin Chim Acta</source><volume>370</volume><fpage>152</fpage><lpage>157</lpage><pub-id pub-id-type="pmid">16545788</pub-id></citation></ref><ref id="pone.0002546-Kumaramanickavel1"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kumaramanickavel</surname><given-names>G</given-names></name><name><surname>Sripriya</surname><given-names>S</given-names></name><name><surname>Vellanki</surname><given-names>RN</given-names></name><name><surname>Upadyay</surname><given-names>NK</given-names></name><name><surname>Badrinath</surname><given-names>SS</given-names></name><etal/></person-group><year>2001</year><article-title>Tumor necrosis factor allelic polymorphism with diabetic retinopathy in India.</article-title><source>Diabetes Res Clin Pract</source><volume>54</volume><fpage>89</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">11640992</pub-id></citation></ref><ref id="pone.0002546-Um1"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Um</surname><given-names>JY</given-names></name><name><surname>An</surname><given-names>NH</given-names></name><name><surname>Kim</surname><given-names>HM</given-names></name></person-group><year>2003</year><article-title>TNF-alpha and TNF-beta gene polymorphisms in cerebral infarction.</article-title><source>J Mol Neurosci</source><volume>21</volume><fpage>167</fpage><lpage>171</lpage><pub-id pub-id-type="pmid">14593215</pub-id></citation></ref><ref id="pone.0002546-Bernard1"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bernard</surname><given-names>V</given-names></name><name><surname>Pillois</surname><given-names>X</given-names></name><name><surname>Dubus</surname><given-names>I</given-names></name><name><surname>Benchimol</surname><given-names>D</given-names></name><name><surname>Labouyrie</surname><given-names>JP</given-names></name><etal/></person-group><year>2003</year><article-title>The -308 G/A tumor necrosis factor-alpha gene dimorphism: a risk factor for unstable angina.</article-title><source>Clin Chem Lab Med</source><volume>41</volume><fpage>511</fpage><lpage>516</lpage><pub-id pub-id-type="pmid">12747595</pub-id></citation></ref><ref id="pone.0002546-Ozaki1"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ozaki</surname><given-names>K</given-names></name><name><surname>Ohnishi</surname><given-names>Y</given-names></name><name><surname>Iida</surname><given-names>A</given-names></name><name><surname>Sekine</surname><given-names>A</given-names></name><name><surname>Yamada</surname><given-names>R</given-names></name><etal/></person-group><year>2002</year><article-title>Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction.</article-title><source>Nat Genet</source><volume>32</volume><fpage>650</fpage><lpage>654</lpage><pub-id pub-id-type="pmid">12426569</pub-id></citation></ref><ref id="pone.0002546-Asselbergs1"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Asselbergs</surname><given-names>FW</given-names></name><name><surname>Pai</surname><given-names>JK</given-names></name><name><surname>Rexrode</surname><given-names>KM</given-names></name><name><surname>Hunter</surname><given-names>DJ</given-names></name><name><surname>Rimm</surname><given-names>EB</given-names></name></person-group><year>2006</year><article-title>Effects of lymphotoxin-alpha gene and galectin 2 gene polymorphisms on inflammatory biomarkers, cellular adhesion molecules, and risk of coronary heart disease.</article-title><source>Clin Sci (Lond)</source></citation></ref><ref id="pone.0002546-Li1"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Groop</surname><given-names>L</given-names></name><name><surname>Nilsson</surname><given-names>A</given-names></name><name><surname>Weng</surname><given-names>J</given-names></name><name><surname>Tuomi</surname><given-names>T</given-names></name></person-group><year>2003</year><article-title>A combination of human leukocyte antigen DQB1&#x0002a;02 and the tumor necrosis factor alpha promoter G308A polymorphism predisposes to an insulin-deficient phenotype in patients with type 2 diabetes.</article-title><source>J Clin Endocrinol Metab</source><volume>88</volume><fpage>2767</fpage><lpage>2774</lpage><pub-id pub-id-type="pmid">12788886</pub-id></citation></ref><ref id="pone.0002546-Laki1"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Laki</surname><given-names>J</given-names></name><name><surname>Kiszel</surname><given-names>P</given-names></name><name><surname>Vatay</surname><given-names>A</given-names></name><name><surname>Blasko</surname><given-names>B</given-names></name><name><surname>Kovacs</surname><given-names>M</given-names></name><etal/></person-group><year>2007</year><article-title>The HLA 8.1 ancestral haplotype is strongly linked to the C allele of -429T&#x0003e;C promoter polymorphism of receptor of the advanced glycation endproduct (RAGE) gene. Haplotype-independent association of the -429C allele with high hemoglobin(A1C) levels in diabetic patients.</article-title><source>Mol Immunol</source><volume>44</volume><fpage>648</fpage><lpage>655</lpage><pub-id pub-id-type="pmid">16504296</pub-id></citation></ref><ref id="pone.0002546-Noble1"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Noble</surname><given-names>JA</given-names></name><name><surname>Valdes</surname><given-names>AM</given-names></name><name><surname>Cook</surname><given-names>M</given-names></name><name><surname>Klitz</surname><given-names>W</given-names></name><name><surname>Thomson</surname><given-names>G</given-names></name><etal/></person-group><year>1996</year><article-title>The role of HLA class II genes in insulin-dependent diabetes mellitus: molecular analysis of 180 Caucasian, multiplex families.</article-title><source>Am J Hum Genet</source><volume>59</volume><fpage>1134</fpage><lpage>1148</lpage><pub-id pub-id-type="pmid">8900244</pub-id></citation></ref><ref id="pone.0002546-Single1"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Single</surname><given-names>RM</given-names></name><name><surname>Meyer</surname><given-names>D</given-names></name><name><surname>Hollenbach</surname><given-names>JA</given-names></name><name><surname>Nelson</surname><given-names>MP</given-names></name><name><surname>Noble</surname><given-names>JA</given-names></name><etal/></person-group><year>2002</year><article-title>Haplotype frequency estimation in patient populations: the effect of departures from Hardy-Weinberg proportions and collapsing over a locus in the HLA region.</article-title><source>Genet Epidemiol</source><volume>22</volume><fpage>186</fpage><lpage>195</lpage><pub-id pub-id-type="pmid">11788963</pub-id></citation></ref><ref id="pone.0002546-Hudson1"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hudson</surname><given-names>BI</given-names></name><name><surname>Stickland</surname><given-names>MH</given-names></name><name><surname>Futers</surname><given-names>TS</given-names></name><name><surname>Grant</surname><given-names>PJ</given-names></name></person-group><year>2001</year><article-title>Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy.</article-title><source>Diabetes</source><volume>50</volume><fpage>1505</fpage><lpage>1511</lpage><pub-id pub-id-type="pmid">11375354</pub-id></citation></ref><ref id="pone.0002546-dosSantos1"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>dos Santos</surname><given-names>KG</given-names></name><name><surname>Canani</surname><given-names>LH</given-names></name><name><surname>Gross</surname><given-names>JL</given-names></name><name><surname>Tschiedel</surname><given-names>B</given-names></name><name><surname>Pires Souto</surname><given-names>KE</given-names></name><etal/></person-group><year>2005</year><article-title>The -374A allele of the receptor for advanced glycation end products gene is associated with a decreased risk of ischemic heart disease in African-Brazilians with type 2 diabetes.</article-title><source>Mol Genet Metab</source><volume>85</volume><fpage>149</fpage><lpage>156</lpage><pub-id pub-id-type="pmid">15896660</pub-id></citation></ref><ref id="pone.0002546-Falcone1"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Falcone</surname><given-names>C</given-names></name><name><surname>Campo</surname><given-names>I</given-names></name><name><surname>Emanuele</surname><given-names>E</given-names></name><name><surname>Buzzi</surname><given-names>MP</given-names></name><name><surname>Geroldi</surname><given-names>D</given-names></name><etal/></person-group><year>2005</year><article-title>-374T/A polymorphism of the RAGE gene promoter in relation to severity of coronary atherosclerosis.</article-title><source>Clin Chim Acta</source><volume>354</volume><fpage>111</fpage><lpage>116</lpage><pub-id pub-id-type="pmid">15748606</pub-id></citation></ref><ref id="pone.0002546-Padovani1"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Padovani</surname><given-names>JC</given-names></name><name><surname>Pazin-Filho</surname><given-names>A</given-names></name><name><surname>Simoes</surname><given-names>MV</given-names></name><name><surname>Marin-Neto</surname><given-names>JA</given-names></name><name><surname>Zago</surname><given-names>MA</given-names></name><etal/></person-group><year>2000</year><article-title>Gene polymorphisms in the TNF locus and the risk of myocardial infarction.</article-title><source>Thromb Res</source><volume>100</volume><fpage>263</fpage><lpage>269</lpage><pub-id pub-id-type="pmid">11113269</pub-id></citation></ref><ref id="pone.0002546-Wang1"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Ng</surname><given-names>MC</given-names></name><name><surname>So</surname><given-names>WY</given-names></name><name><surname>Ma</surname><given-names>R</given-names></name><name><surname>Ko</surname><given-names>GT</given-names></name><etal/></person-group><year>2005</year><article-title>Association between tumour necrosis factor-alpha G-308A polymorphism and risk of nephropathy in obese Chinese type 2 diabetic patients.</article-title><source>Nephrol Dial Transplant</source><volume>20</volume><fpage>2733</fpage><lpage>2738</lpage><pub-id pub-id-type="pmid">16141456</pub-id></citation></ref><ref id="pone.0002546-Zeggini1"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zeggini</surname><given-names>E</given-names></name><name><surname>Groves</surname><given-names>CJ</given-names></name><name><surname>Parkinson</surname><given-names>JR</given-names></name><name><surname>Halford</surname><given-names>S</given-names></name><name><surname>Owen</surname><given-names>KR</given-names></name><etal/></person-group><year>2005</year><article-title>Large-scale studies of the association between variation at the TNF/LTA locus and susceptibility to type 2 diabetes.</article-title><source>Diabetologia</source><volume>48</volume><fpage>2013</fpage><lpage>2017</lpage><pub-id pub-id-type="pmid">16132956</pub-id></citation></ref><ref id="pone.0002546-Yeh1"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yeh</surname><given-names>CH</given-names></name><name><surname>Sturgis</surname><given-names>L</given-names></name><name><surname>Haidacher</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>XN</given-names></name><name><surname>Sherwood</surname><given-names>SJ</given-names></name><etal/></person-group><year>2001</year><article-title>Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion.</article-title><source>Diabetes</source><volume>50</volume><fpage>1495</fpage><lpage>1504</lpage><pub-id pub-id-type="pmid">11375353</pub-id></citation></ref><ref id="pone.0002546-Barrett1"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Fry</surname><given-names>B</given-names></name><name><surname>Maller</surname><given-names>J</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name></person-group><year>2005</year><article-title>Haploview: analysis and visualization of LD and haplotype maps.</article-title><source>Bioinformatics</source><volume>21</volume><fpage>263</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">15297300</pub-id></citation></ref><ref id="pone.0002546-Purcell1"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Purcell</surname><given-names>S</given-names></name><name><surname>Cherny</surname><given-names>SS</given-names></name><name><surname>Sham</surname><given-names>PC</given-names></name></person-group><year>2003</year><article-title>Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits.</article-title><source>Bioinformatics</source><volume>19</volume><fpage>149</fpage><lpage>150</lpage><pub-id pub-id-type="pmid">12499305</pub-id></citation></ref><ref id="pone.0002546-Kalinowski1"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kalinowski</surname><given-names>ST</given-names></name></person-group><year>2006</year><article-title>hw-quickcheck: an easy-to-use computer program for checking genotypes for agreement with Hardy-Weinberg expectations.</article-title><source>Molecular Ecology Notes</source><volume>6</volume><fpage>974</fpage><lpage>979</lpage></citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>This study was supported by Skane County Council Research and Development Foundation and the Medical Research Council of Lundberg.</p></fn></fn-group></back></article> 